Prestige BioPharma Limited

KSE 950210.KS

Prestige BioPharma Limited Cash and Short-Term Investments for the year ending June 30, 2024: USD 165.66 M

Prestige BioPharma Limited Cash and Short-Term Investments is USD 165.66 M for the year ending June 30, 2024, a -27.30% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Prestige BioPharma Limited Cash and Short-Term Investments for the year ending June 30, 2023 was USD 227.87 M, a -2.80% change year over year.
Prestige BioPharma Limited Cash and Short-Term Investments for the year ending June 30, 2022 was USD 234.43 M, a -42.01% change year over year.
Prestige BioPharma Limited Cash and Short-Term Investments for the year ending June 30, 2021 was USD 404.23 M, a 906.27% change year over year.
Prestige BioPharma Limited Cash and Short-Term Investments for the year ending June 30, 2020 was USD 40.17 M, a 374.80% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

KSE: 950210.KS

Prestige BioPharma Limited

CEO	Ms. So-Yeon Park
IPO Date	Feb. 9, 2021
Location	Singapore
Headquarters	21 Biopolis Road
Employees	66
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals Plastics Vaccines

Description

Prestige BioPharma Limited, a biopharmaceutical company, engages in the research, development, and marketing of biosimilars and new antibody therapeutics in the Asia Pacific. The company primarily engages in the development of new and similar antibody drugs for solid tumor, pancreatic cancer, breast cancer, gastric cancer, and arthritis. It is also developing vaccines for COVID-19 virus. The company was incorporated in 2015 and is headquartered in Singapore.

Key trends

Past 5 years